| Abhorring the vacuum: use of Alzheimer’s disease medications in frontotemporal dementia. | |
| | |
MedLine Citation:
|
PMID: 21728274 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
There is no dedicated therapy for frontotemporal dementia (FTD). In order to treat the often devastating behavioral disturbances that interfere with both normal social functioning and the ability of caregivers to provide needed support, off-label medication usage is frequent. In addition to antidepressant and antipsychotic medications, which afford some benefits, US FDA-approved treatments for Alzheimer's disease are often used, including both cholinesterase inhibitors and memantine. Here, we review the various clinical manifestations of FTD, a general approach to treatment and the goals of any potential therapies. We review all of the existing literature on the use of cholinesterase inhibitors and memantine in FTD. While cholinesterase inhibitors do not currently have a place in FTD treatment, memantine may be helpful, although the results of two placebo-controlled trials with this agent are not yet available. Finally, we discuss our view that such approaches will probably become supplanted by rational, molecularly-based therapies currently in development. |
| | |
Authors:
|
Geoffrey A Kerchner; Maria Carmela Tartaglia; Adam Boxer |
Related Documents
:
|
12649554 - Seeds of discord: the politics of radon therapy in canada in the 1930s. 15554604 - Clinicians' autonomy till the bitter end--can we learn from the extraordinary case of h... 17260914 - Divesting strategies for medical practices. 16148254 - The proliferation of clinical practice guidelines: professional development or medicine... 15754814 - Quality quagmire. why systems and processes are important to your practice but often ig... 16402504 - Dangerous dissections: the hazard from bodies supplied to edinburgh anatomists, winter ... |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: Expert review of neurotherapeutics Volume: 11 ISSN: 1744-8360 ISO Abbreviation: Expert Rev Neurother Publication Date: 2011 May |
Date Detail:
|
Created Date: 2011-07-01 Completed Date: 2011-07-12 Revised Date: 2012-03-07 |
Medline Journal Info:
|
Nlm Unique ID: 101129944 Medline TA: Expert Rev Neurother Country: England |
Other Details:
|
Languages: eng Pagination: 709-17 Citation Subset: IM |
Affiliation:
|
Stanford Center for Memory Disorders, Stanford University Medical Center, 300 Pasteur Drive, Room A343, Stanford, CA 94305-5235, USA. kerchner@stanford.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Alzheimer Disease
/
drug therapy Cholinesterase Inhibitors / therapeutic use* Dopamine Agents / therapeutic use* Frontotemporal Dementia / classification, drug therapy*, physiopathology Humans Memantine / therapeutic use* Off-Label Use* Pharmacogenetics / trends |
| Grant Support | |
ID/Acronym/Agency:
|
K23 NS048855-01A1/NS/NINDS NIH HHS; K23 NS048855-02/NS/NINDS NIH HHS; K23 NS048855-03/NS/NINDS NIH HHS; K23 NS048855-04/NS/NINDS NIH HHS; K23 NS048855-05/NS/NINDS NIH HHS; K23NS48855/NS/NINDS NIH HHS; R01 AG031278-01A2/AG/NIA NIH HHS; R01 AG031278-02/AG/NIA NIH HHS; R01 AG031278-03/AG/NIA NIH HHS; R01 AG031278-04/AG/NIA NIH HHS; R01 AG038791-01/AG/NIA NIH HHS; R01 AG038791-02/AG/NIA NIH HHS; R01AG031278/AG/NIA NIH HHS; R01AG038791/AG/NIA NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Cholinesterase Inhibitors; 0/Dopamine Agents; 19982-08-2/Memantine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Relationship between ankle brachial index (ABI), high sensitivity C-reactive protein (hs-CRP) and in...
Next Document: Assessing Equitable Access to Urban Green Space: The Role of Engineered Water Infrastructure.